Acute hepatitis C

Hepatology

Volumn 33, Issue 2, 2001, Pages 321-327

  Orland, Jennie R ^a   Wright, Teresa L ^a   Cooper, Stewart ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEPATITIS; CELLULAR IMMUNITY; CLINICAL FEATURE; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; PRIORITY JOURNAL; SERODIAGNOSIS; SHORT SURVEY; VIROLOGY; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION;

EID: 0035140818     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.22112     Document Type: Article

References (74)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
3. The natural history of community-acquired hepatitis C in the United States
4. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
5. Hepatitis C: The clinical spectrum of disease
6. Hepatitis C: The clinical spectrum of the disease
7. Hepatitis C virus viremia following clinical resolution of acute hepatitis C
8. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
9. IgM antibody to hepatitis C virus in acute and chronic hepatitis C
10. Immunoglobulin G and M hepatitis C virus core antibody (JCC.2) response in chimpanzees infected experimentally with hepatitis C virus
11. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III
12. Modeling age- and time-specific incidence from seroprevalence: Toxoplasmosis
13. Epidemiology of hepatitis C in the United States
14. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
15. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
16. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
17. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus
18. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
19. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
20. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
21. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients
22. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient
23. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
24. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope
25. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence
26. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
27. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor
28. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
29. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: Reevaluation of the role of HCV in liver disease
30. Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to detection of HCV RNA in blood
31. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles
32. Analysis of a successful immune response against hepatitis C virus
33. Immunoglobulin M anti-body to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome
34. Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C
35. Absence of anti-envelope antibodies and clearance of hepatitis C virus in a cohort of Irish Women infected in 1977
36. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
37. Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization
38. Vaccination of chimpanzees against infection by the hepatitis C virus
39. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus
40. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin
41. Clinical outcome of hypogamma globulinaemic patients following outbreak of acute hepatitis C: 2 year follow up
42. Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children
43. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
44. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection
45. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
46. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
47. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
48. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice
49. Role of the specific T-cell response for clearance and control of hepatitis C virus
50. Viral clearance without destruction of infected cells during acute HBV infection
51. A major histocompatibility complex class I allele shared by two species of chimpanzee
52. Comparison of class I MHC alleles in humans and apes
53. Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates
54. Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates
55. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
56. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
57. Apoptosis within spontaneously accepted mouse liver allografts: Evidence for deletion of cytotoxic T cells and implications for tolerance induction
58. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: Enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis
59. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients
60. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons
61. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis
62. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
63. Resolution of acute hepatitis C after therapy with natural beta interferon
64. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
65. Outcome of acute hepatitis C and role of interferon alpha therapy
66. Interferon-alpha in acute post-transfusion hepatitis C: A randomized, controlled trial
67. Interferon therapy for acute hepatitis C: Changes in serum markers associated with HCV and clinical effects
68. A report on therapy of interferon-A2b in patients with acute hepatitis C
69. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: A pilot study
70. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
71. Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis
72. Treatment of acute hepatitis C virus infection
73. Natural beta interferon in acute type-C hepatitis patients: A randomized controlled trial
74. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C